Related Experiment Video
Updated: Jul 20, 2026

Targeting Drugs to Larval Zebrafish Macrophages by Injecting Drug-Loaded Liposomes
Published on: February 18, 2020
Selective targeting of liposomes to macrophages using a ligand with high affinity for the macrophage scavenger
Patrick C N Rensen1, J C Emile Gras, Eva K Lindfors
1Dept. of Endocrinology and Metabolic Diseases, Leiden University Medical Center, C4-R81, Albinusdreef 2, P.O. Box 9600, 2300 RC Leiden, The Netherlands. P.C.N.Rensen@lumc.nl
Abstract:
Macrophages play an important role in inflammatory processes and are crucially involved in the onset and progression of atherosclerosis and tumorigenesis. Therefore, macrophages are regarded as an excellent target for therapeutic intervention. Since the scavenger receptor class A (SRA) is highly expressed on macrophages, we developed in the present study an SRA-specific particulate drug carrier by providing phosphatidylcholine liposomes with a targeting ligand for SRA. To enable firm association with liposomes, the high-affinity SRA ligand decadeoxyguanine was covalently attached via a linker to lithocholic oleate (LCO-dA(2)dG(10)). Incorporation of LCO-dA(10)dG(2) into liposomes resulted in an increased electronegative surface charge and a dramatically enhanced serum clearance (t(1/2) < 2 min versus > 5 h). The LCO-dA(2)dG(10)-induced liposome clearance was fully dependent on SRA, as the clearance could be efficiently inhibited by the SRA competitor polyinosinic acid. LCO-dA(2)dG(10) enhanced the affinity of liposomes for SRA in vivo selectively, since introduction of overall or clustered negative charges by other modifications (e.g. oxidation, inclusion of phosphatidylserine, or exposure of glutamic acid residues) did not affect their serum clearance substantially, albeit that these modifications resulted in an at least equally high negative surface charge. LCO-dA(2)dG(10) also increased the association of liposomes with RAW264.7 cells, resulting in an enhanced intracellular delivery and bioactivity of encapsulated dexamethasone-phosphate. Therefore, the SRA-specificity of LCO-dA(2)dG(10)-liposomes may be applied for the specific delivery of drugs to macrophages, which may be of therapeutic benefit in general inflammatory disorders, atherosclerosis, and tumorigenesis.
Insights
Researchers developed SRA-specific liposomes using a novel ligand for targeted drug delivery to macrophages. This approach enhances drug efficacy for inflammatory diseases, atherosclerosis, and cancer.
Area of Science:
- Biomedical Engineering
- Drug Delivery Systems
- Immunology
Background:
- Macrophages are key players in inflammation, atherosclerosis, and cancer.
- Targeting macrophages offers therapeutic potential for various diseases.
- Scavenger Receptor A (SRA) is highly expressed on macrophages, making it an attractive target.
Purpose of the Study:
- To develop SRA-specific liposomes for targeted drug delivery to macrophages.
- To investigate the efficacy of a novel SRA-targeting ligand (LCO-dA2dG10) incorporated into liposomes.
- To evaluate the impact of these targeted liposomes on drug delivery and therapeutic outcomes.
Main Methods:
- Covalent attachment of a high-affinity SRA ligand (decadeoxyguanine) to lithocholic oleate (LCO-dA2dG10).
- Incorporation of LCO-dA2dG10 into phosphatidylcholine liposomes to create SRA-specific drug carriers.
- In vivo assessment of liposome serum clearance, SRA-dependency, and cellular association.
- Evaluation of intracellular drug delivery and bioactivity of encapsulated dexamethasone-phosphate.
Main Results:
- LCO-dA2dG10-liposomes exhibited rapid serum clearance (<2 min) dependent on SRA.
- SRA-specific targeting was confirmed, as clearance was inhibited by SRA competitors.
- Other negative surface charge modifications did not yield similar clearance profiles, highlighting LCO-dA2dG10's unique SRA-enhancement.
- Targeted liposomes increased association with RAW264.7 cells and enhanced intracellular delivery of dexamethasone-phosphate.
Conclusions:
- LCO-dA2dG10-liposomes demonstrate high specificity for SRA on macrophages.
- This targeted delivery system enhances drug uptake and bioactivity within macrophages.
- SRA-specific liposomes hold therapeutic promise for inflammatory disorders, atherosclerosis, and tumorigenesis.
Related Concept Videos
Receptor-mediated Endocytosis
Receptor-mediated Endocytosis
Clathrin-Mediated Endocytosis of LDL
One well-characterized example of receptor-mediated endocytosis is the...
